Navigation Links
Two-dimensional Optimization of a Semi-nested PCR,,, for Detecting Listeria monocytogenes

ange, reached a plateau at 57.6C 58.9C and then dropped dramatically. The highest OD values, and thus the highest product yield, was obtained at a temperature of 58C.

Verifying the optima determined (Fig. 5)

Under the optimized conditions (3 mM MgCl2, 58C annealing temperature), the initial experiment was repeated with the DNA amounts from 20 pg to 2 fg.
The optimized system enabled 20 fg DNA to be detected in the initial PCR L1/L4, which is equivalent to a tenfold reduction in the detection limit. The subsequent semi-nested PCR produced an unequivocally positive result based on 20 fg DNA.

Fig. 2: First optimization of the initial PCR (primer pair L1/L4) by varying the MgCl2 concentration (1.5 mM 3.5 mM) and by applying a temperature gradient (58C 70C). 20 fg Listeria monocytogenes DNA was used in each case. Fig. 3. Limiting the annealing temperature for the initial PCR (primer pair L1/L4) by applying a temperature gradient (55C 65C; 3 mM MgCl2). 20 fg Listeria monocytogenes DNA was used in each case. Fig. 4. Densitometric evaluation of the bands of agarose gel from Fig. 3. Evaluation was performed using RFLP Scan from S
'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. PCR Optimization
2. PCR Optimization Kit
3. The Flexible matriXarray Chip System: A New Perspective for Probe Optimization in Gene-Expression Profiling
4. Rapid Chromatography Optimization by pH Scouting Using the New BioLogic Maximizer Valve System, Rev A
5. The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B
6. Optimization of Biolistic Transformation Using the Helium-Driven PDS-1000/He System
7. Simple Approaches for Optimization of RT-PCR
8. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
9. Unique DNA Polymerase Formulation Excels in a Broad Range of PCR Applications
10. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
11. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue

Post Your Comments:
(Date:11/24/2009)...e-FirstCall/--IES(Nasdaq: IESC ),aleadingnationalp...icesforthecommercial,industrialandresidentialmarke...beenawardedacontractfromManhattanTorconJVtoinstall...4)replacementfacilityattheU.S.ArmyMedicalResearchI...kinFrederick,Md. ,, ThenewUSAMRIIDreplacementfa...
(Date:11/24/2009)...w York investment bank KTA Capital,s client Neuren...7 mil convertible note private placement with a U....as arranged by KTA Capital as Neuren,s exclusive p... New York (PRWEB) November 23, 2009 -- The ind... ("KTA Capital") has announced that its ...
(Date:11/24/2009)...io,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCa...eds,adivisionofThompsonsLimitedofBlenheim,Ontario....iences,currentseedsbusinessasthecompanyanticipates...roSciencesHerbicideTolerantTraitTechnologyincornin...e. ,, "Thisacquisitionbringstogethertwostrongpr...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...rovide sustained tumor exposure to platinum and pr...icity observed in the clinic - , , DALLAS, April ...oard: ACCP) announced today that its collaborato... preclinical data on its lead anticancer compound,...ncer Research (AACR) Annual Meeting taking place A...
...April 21 /PRNewswire-Asia/ --,QIAGEN and the Chitt...ounced a,collaboration to establish the first larg...n in Kolkata, India. QIAGEN (Nasdaq: QGEN ; Fra...ostic tests for the human papillomavirus,(HPV) -- ...nduct the screening,and provide appropriate treatm...
...L ), a leading, global full-service clinical resea... meet analyst expectations for the first quarter o...ecedented biopharmaceutical industry conditions, w... of contracts on existing awards, fewer new reques...llations and delays. The Company now expects net s...
Other Biology Technology:Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting 2Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting 3Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting 4QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 2QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 3QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 4QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 5Kendle to Host Conference Call to Discuss Revised 2009 Outlook 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 3
(Date:11/24/2009)...s opening new doors to understanding how sounds as...of a marine mammal or if they hear it at all. , ...nners that NASA uses to detect flaws in the space ...ing scientists to peek inside the giant head of a ...nsional replicas of a whale,s hearing anatomy usin...
(Date:11/24/2009)... weakened and flabby arteries from collapsing have...e stents are no longer needed -- once the arteries...usly, doctors had no choice but to leave them in p...rsity,s Department of Biomedical Engineering has d...carries drugs where they,re needed, then dissolves...
(Date:11/24/2009)... American College of Medical Toxicology (ACMT) hav...ation of the Journal of Medical Toxicology (JMT)...arch 2010. It was previously published by the Uni...f Medical Toxicology , an international, peer-revi...e and practice of medical toxicology. The quarter...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 1Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 2Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 3Brookhaven Lab and Hybridyne Imaging Technologies Inc win R 26amp 3BD 100 award 52619 1Brookhaven Lab and Hybridyne Imaging Technologies Inc win R 26amp 3BD 100 award 52619 2Brookhaven Lab and Hybridyne Imaging Technologies Inc win R 26amp 3BD 100 award 52619 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 1R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 8
...dy of 20,000 people found seven new genes that inf... heart disease, and confirmed 11 other genes prev...nternational study led by researchers from the Uni...t to identify or confirm genetic variants that inf... variants were linked to the decreased or increase...
...he human genome, researchers have associated level...e blood, to 18 genetic variants, six of which repr... the traits. The findings, appearing in the Januar... explain some of the variability in cholesterol an... the potential to help predict a patients genetic ...
...) brings experts to New York City from around the ...ce on Cell Therapy for Cardiovascular Diseases. De...e three-day session will feature an in-depth revie...d regeneration, angiogenesis and cutting-edge rese...al Focus: Full-day programs for the discussion of...
Other Biology News:Study locates cholesterol genes; finds surprises about good, bad cholesterol 2Scientists associate 6 new genetic variants with heart disease risk factor 2Scientists associate 6 new genetic variants with heart disease risk factor 3Scientists associate 6 new genetic variants with heart disease risk factor 4Cell Therapy for Cardiovascular Diseases 2Cell Therapy for Cardiovascular Diseases 3
Stainless Steel Glove Boxes from Terra Universal, Inc.
...n filter/fan unit provides continuous vertical flo...SO 5) cleanliness standards , Stainless steel en...ergonomically sloped polycarbonate viewing window ...or other large process equipment , Isolated ante...
Heated Processing Chamber from Terra Universal, Inc.
Down Draft Work Station from Terra Universal, Inc.
Biology Products: